Loading...
•
Dec 31, 2023
Theravance Q4 2023 Earnings Report
Announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
Key Takeaways
Theravance Biopharma reported strong performance in 2023, achieving financial objectives in the fourth quarter and exceeding the annual goal for YUPELRI hospital growth. The company looks forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of the year.
Theravance team delivered a strong performance in 2023.
Achieved financial objectives in the fourth quarter.
Exceeded aggressive annual goal for YUPELRI hospital growth.
Completing enrollment in the CYPRESS study in the second half of this year.
Theravance
Theravance
Theravance Revenue by Segment
Revenue by Segment
YUPELRI Collaboration Revenue
CapyFin.com Forward Guidance
Theravance Biopharma expects to continue YUPELRI net sales growth in 2024 and complete enrollment in the CYPRESS study in the second half of this year.